|
| 37975877 | Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development. | J Natl Cancer Inst | 2024 |
| 36637394 | Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma. | Mol Cancer Res | 2023 |
| 37549914 | Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37073685 | Germline genomic findings in children and young adults with melanocytic tumors. | Pediatr Blood Cancer | 2023 |
| 37364199 | UVEAL MELANOMA PRESENTING AS HEPATIC METASTASIS IN A PATIENT WITH OCULODERMAL MELANOCYTOSIS. | Retin Cases Brief Rep | 2023 |
| 36997313 | Progressive metastatic infantile fibrosarcoma with multiple acquired mutations. | Cold Spring Harb Mol Case Stud | 2023 |
| 37194488 | Feasibility of indocyanine green-guided localization of pulmonary nodules in children with solid tumors. | Pediatr Blood Cancer | 2023 |
| 36764878 | Adaptive Proton Therapy for Pediatric Parameningeal Rhabdomyosarcoma: On-Treatment Anatomic Changes and Timing to Replanning. | Clin Oncol (R Coll Radiol) | 2023 |
| 34625800 | Light Therapy for QoL/Depression in AYA With Cancer: A Randomized Trial. | J Pediatr Psychol | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 35830886 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35483358 | The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. | Dev Cell | 2022 |
| 36074012 | Top advances of the year: Pediatric oncology. | Cancer | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36328007 | ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development? | Lancet Oncol | 2022 |
| 36351335 | NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. | J Natl Compr Canc Netw | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 35119937 | Antigen cross-presentation in young tumor-bearing hosts promotes CD8<sup>+</sup> T cell terminal differentiation. | Sci Immunol | 2022 |
| 34871104 | Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. | J Clin Oncol | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 32746639 | Feasibility and Acceptability of Light Therapy to Reduce Fatigue in Adolescents and Young Adults Receiving Cancer-Directed Therapy. | Behav Sleep Med | 2021 |
| 33822640 | Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. | J Clin Oncol | 2021 |
| 33637564 | The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. | Cancer Res | 2021 |
| 33497361 | Developmental vascular malformations in EPAS1 gain-of-function syndrome. | JCI Insight | 2021 |
| 34623899 | Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. | J Clin Oncol | 2021 |
| 34301788 | Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. | Cancer Discov | 2021 |
| 34174159 | Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. | Pediatr Blood Cancer | 2021 |
| 34228509 | Reply to J.-G. Wang et al. | J Clin Oncol | 2021 |
| 34228365 | A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. | Cancer | 2021 |
| 33408242 | St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. | Cancer Discov | 2021 |
| 33369896 | Pain and functional outcomes in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study. | Cancer | 2021 |
| 33259934 | Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. | Int J Radiat Oncol Biol Phys | 2021 |
| 30963398 | Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. | Ann Surg Oncol | 2020 |
| 31876943 | Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. | JAMA Ophthalmol | 2020 |
| 31876082 | Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. | Pediatr Blood Cancer | 2020 |
| 32060267 | MYCN amplification and ATRX mutations are incompatible in neuroblastoma. | Nat Commun | 2020 |
| 31812554 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 |
| 31786124 | A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. | Lancet Oncol | 2020 |
| 31987969 | Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study. | Int J Radiat Oncol Biol Phys | 2020 |
| 32105622 | Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. | Lancet Oncol | 2020 |
| 33285515 | NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. | J Natl Compr Canc Netw | 2020 |
| 32637605 | XAF1 as a modifier of p53 function and cancer susceptibility. | Sci Adv | 2020 |
| 32630797 | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. | Cancers (Basel) | 2020 |
| 32795876 | A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. | Eur J Cancer | 2020 |
| 32729886 | Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. | JAMA Oncol | 2020 |
| 32923911 | Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring <i>RET</i> Gene Alterations. | JCO Precis Oncol | 2020 |
| 32695311 | Recent advances in understanding and managing pediatric rhabdomyosarcoma. | F1000Res | 2020 |
| 32499311 | Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study. | Cancer Epidemiol Biomarkers Prev | 2020 |